Allena Pharmaceuticals (ALNA) Receives Consensus Rating of “Buy” from Analysts

Share on StockTwits

Allena Pharmaceuticals (NASDAQ:ALNA) has received a consensus rating of “Buy” from the eight research firms that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $32.90.

Several equities research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Allena Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, May 11th. ValuEngine raised shares of Allena Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. B. Riley assumed coverage on shares of Allena Pharmaceuticals in a research report on Wednesday, April 25th. They set a “buy” rating and a $23.50 price objective for the company. Roth Capital assumed coverage on shares of Allena Pharmaceuticals in a research report on Monday, April 2nd. They set a “buy” rating and a $61.00 price objective for the company. Finally, Credit Suisse Group decreased their price objective on shares of Allena Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research report on Wednesday, March 28th.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. lifted its position in Allena Pharmaceuticals by 2.2% in the first quarter. BlackRock Inc. now owns 231,654 shares of the company’s stock valued at $2,553,000 after acquiring an additional 4,879 shares during the last quarter. Wells Fargo & Company MN lifted its position in Allena Pharmaceuticals by 246.4% in the first quarter. Wells Fargo & Company MN now owns 9,336 shares of the company’s stock valued at $103,000 after acquiring an additional 6,641 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in Allena Pharmaceuticals in the fourth quarter valued at $102,000. Citadel Advisors LLC purchased a new stake in Allena Pharmaceuticals in the first quarter valued at $124,000. Finally, Deutsche Bank AG purchased a new stake in Allena Pharmaceuticals in the fourth quarter valued at $118,000. 82.24% of the stock is owned by hedge funds and other institutional investors.

Allena Pharmaceuticals traded down $0.07, hitting $13.50, during midday trading on Monday, MarketBeat Ratings reports. The company’s stock had a trading volume of 71,227 shares, compared to its average volume of 101,241. The company has a quick ratio of 12.06, a current ratio of 12.06 and a debt-to-equity ratio of 0.06. Allena Pharmaceuticals has a 52-week low of $6.13 and a 52-week high of $17.56. The stock has a market capitalization of $280.84 million and a PE ratio of -2.81.

Allena Pharmaceuticals (NASDAQ:ALNA) last issued its quarterly earnings results on Tuesday, May 8th. The company reported ($0.38) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.05. analysts expect that Allena Pharmaceuticals will post -1.92 EPS for the current fiscal year.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

Analyst Recommendations for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply